Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.31 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777217 | 1.00 | LSS (0.35) | LSSDPP7NAMPTTEAD1TEAD3 | |
| SCHEMBL21780525 | 0.83 | PRMT5 (0.45) | — | |
| SCHEMBL21767675 | 0.82 | LSS (0.39) | LSSNAMPTTEAD1TEAD3TAAR1 | |
| SCHEMBL21767671 | 0.82 | LSS (0.39) | LSSNAMPTTEAD1TEAD3TAAR1 | |
| SCHEMBL31063190 | 0.82 | PRMT5 (0.44) | LSS | |
| SCHEMBL30094731 | 0.81 | LSS (0.40) | LSSNAMPTTEAD1TEAD3TAAR1 | |
| SCHEMBL21780594 | 0.80 | — | — | |
| SCHEMBL21787309 | 0.80 | — | — | |
| SCHEMBL21767475 | 0.78 | NAMPT (0.33) | LSSNAMPTTAAR1 | |
| SCHEMBL21767473 | 0.78 | NAMPT (0.33) | LSSNAMPTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11021480-B2 | Inhibiting (α-V)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| CN-112805001-A | Inhibition of alpha v beta 6 integrins | 莫菲克医疗股份有限公司 | 2021-05-14 | — | — | CN | disclosed |
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHRÖDINGER, LLC | 2020-12-10 | — | — | US | disclosed |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-05 | — | — | US | disclosed |
| EP-3617206-A1 | INTEGRIN INHIBITORS | Morphic Therapeutic, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | ITGB6, ITGA6, GP6 | LSS 3875/4885DPP7 508/4885NAMPT 513/4885 |
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | LSS 3204/4885DPP7 792/4885NAMPT 489/4885 |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | LSS 3204/4885DPP7 792/4885NAMPT 489/4885 |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | LSS 3204/4885DPP7 792/4885NAMPT 489/4885 |
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | LSS 3204/4885DPP7 792/4885NAMPT 489/4885 |
| US-11021480-B2 | Inhibiting (α-V)(β-6) integrin | ITGB6, ITGA6, ITGAV | LSS 3223/4885DPP7 675/4885NAMPT 384/4885 |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | LSS 3223/4885DPP7 675/4885NAMPT 384/4885 |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | LSS 3193/4885DPP7 799/4885NAMPT 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.